Related references
Note: Only part of the references are listed.Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph plus chronic myeloid leukemia in chronic phase
Richard A. Larson et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results
P. D. le Coutre et al.
LEUKEMIA (2012)
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results
Hagop M. Kantarjian et al.
BLOOD (2011)
The small-molecule tyrosine kinase inhibitor nilotinib is a potent noncompetitive inhibitor of the SN-38 glucuronidation by human UGT1A1
Ken-ichi Fujita et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Extended kinase profile and properties of the protein kinase inhibitor nilotinib
Paul W. Manley et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2010)
Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism
C-F Xu et al.
BRITISH JOURNAL OF CANCER (2010)
Hyperbilirubinemia in Lapatinib Treated Patients Is Associated with Gilbert's SyndromeUGT1A1Polymorphism.
C. Spraggs et al.
CANCER RESEARCH (2010)
Clinical Pharmacokinetics of the BCR-ABL Tyrosine Kinase Inhibitor Nilotinib
C. Tanaka et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemia
Amber Fullmer et al.
EXPERT OPINION ON PHARMACOTHERAPY (2010)
Effect of Grapefruit Juice on the Pharmacokinetics of Nilotinib in Healthy Participants
Ophelia Q. P. Yin et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib
Judith Meza-Junco et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
Timothy Hughes et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia
J. B. Singer et al.
LEUKEMIA (2007)
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation
DL Zhang et al.
DRUG METABOLISM AND DISPOSITION (2005)
Mechanism of indinavir-induced hyperbilirubinemia
SD Zucker et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Share Paper
